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Is Splitting Into Distinct Phenotypes by Comorbidities
the Pathway Forward?*Mathew S. Maurer, MD, Donna Mancini, MDA mong the numerous comorbidities that canconfound the diagnosis of heart failure witha preserved ejection fraction (HFpEF), dia-
betes is among the most prevalent. Approximately
one-third of patients with HFpEF have diabetes
(1,2), and as many as half of patients hospitalized
with HFpEF are diabetic (3). Not only is diabetes asso-
ciated with worse outcomes patients with HFpEF (4),
but it is an independent predictor of incident heart
failure (5). Given the lack of efﬁcacy of pharmacolog-
ical therapy for HFpEF, there is a growing focus on
the role of comorbidities in the genesis of this he-
terogeneous clinical syndrome (6) with an emerging
hypothesis that comorbidities drive phenotypic ex-
pression (7). Characterization of HFpEF stratiﬁed by
subgroups may identify relevant cohorts for investiga-
tion and targetable pathophysiological mechanisms.SEE PAGE 541In this issue of the Journal, the RELAX (Evaluating
the Effectiveness of Sildenaﬁl at Improving Health
Outcomes and Exercise Ability in People With Dia-
stolic Heart Failure) investigators report on their
analysis of clinical features, exercise capacity, and
outcomes in patients with HFpEF with or without
diabetes (8). RELAX, a multicenter, randomized trial
of sildenaﬁl versus placebo in HFpEF, enrolled a
small but well-characterized cohort of older adults
with HFpEF using functional, biomarker, echocar-
diographic, and cardiac magnetic resonance mea-
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paper to disclose.exercise capacity as determined by cardiopulmonary
exercise testing and elevated pulmonary capillary
wedge pressures or natriuretic peptides. RELAX was a
negative trial (9), and diabetes had no effect on the
primary endpoint of exercise capacity or the effect of
study drug on hospitalizations.
In this substudy (8), HFpEF with diabetes was
characterized by a younger, more frequently male
and obese cohort with multimorbidity (e.g., more
hypertension, renal dysfunction). Biomarkers showed
evidence of chronic inﬂammation, increased ﬁbrosis,
and higher endothelin-1 levels. Diabetic patients with
HFpEF had more ventricular hypertrophy, but ven-
tricular function did not differ between cohorts. Peak
oxygen uptake and 6-min walk distance were lower in
diabetic patients after controlling for relevant con-
founders (age, sex, body mass index, hemoglobin,
and chronotropic incompetence), whereas hospitali-
zation for renal and cardiac causes was 4 times more
likely.
These differences suggest that diabetic patients
with HFpEF may differ signiﬁcantly from those
without diabetes, but several limitations of the study
should be noted. First, the diagnosis of diabetes was
not based on any formal criteria and not adjudicated
centrally. There were no measures of diabetic severity
or duration, which did not allow exploration of the
relationship between diabetic control and/or severity
with phenotypic expression. Another limitation is the
small sample size, which limits the power to detect
signiﬁcant differences between cohorts with a strong
potential for a type II error. Further evaluation of
differences between HFpEF patients with and without
diabetes in larger trials could provide important
conﬁrmation, clariﬁcation, or revision of these ﬁnd-
ings. In fact, the relatively selective nature of the
RELAX population could minimize important differ-
ences with regard to concomitant renal dysfunction
and anemia.
J A C C V O L . 6 4 , N O . 6 , 2 0 1 4 Maurer and Mancini
A U G U S T 1 2 , 2 0 1 4 : 5 5 0 – 2 HFpEF: Making a Case for Splitting Into Phenotypes
551Finally, the absence of hemodynamic characteriza-
tion during exercise is a limitation because the cause of
exercise intolerance (e.g., central vs. peripheral fac-
tors) in HFpEF patients with diabetes is unknown.
There are multiple mechanisms by which diabetes
could contribute to the phenotypic expression of
HFpEF. Previous studies demonstrated expanded
plasma volumes in patients with HFpEF (10), which is
inﬂuenced by comorbidities of diabetes, anemia,
renal dysfunction, and obesity. This results in altered
pressure volume relations with shifts in noninvasive
estimates of the end-diastolic pressure volume re-
lations downward and rightward (e.g., increased ca-
pacitance) (11), which is consistent with a phenotype
of a high-output state (1) and eccentric remodeling.
Additionally, comorbidities induce a systemic proin-
ﬂammatory state (7), causing microvascular endo-
thelial inﬂammation, which can contribute to altered
cardiomyocyte biology, interstitial ﬁbrosis, hyper-
trophy, and altered ventricular vascular coupling.
Indeed, endothelial dysfunction has been shown to
have independent prognostic signiﬁcance in HFpEF
(12). Chronotropic incompetence is an important
mechanism of exercise intolerance (8). Altered auto-
nomic control is a known complication of diabetes,
which affects baroreﬂex-mediated control of sym-
pathovagal balance. Altered baroreﬂex control has
been shown in animals to contribute to intolerance of
volume loading in the absence of left ventricular
dysfunction and may be important in the genesis of
acute pulmonary edema (13) and impaired cardiac
output response and blood ﬂow to exercising mus-
cles. Finally, diabetes is strongly linked to obesity,
speciﬁcally a phenotypic of sarcopenic obesity, which
can contribute to the reduced exercise performance
in patients with HFpEF (14).
Peripheral mechanisms also may be key media-
tors of the reduced exercise capacity in HFpEF
with diabetes. Prolonged hyperglycemia, hypo- or
hyperinsulinemia, and hyperlipidemia with eleva-
tions in triglycerides and nonesteriﬁed fatty acidscan contribute to skeletal muscle dysfunction.
Additionally, inﬂammatory mediators produced by
adipose tissue might alter myocardial, vascular (both
arterial and venous), and skeletal muscle mass,
quality, and perfusion.
Given the high event rate among diabetic patients
with HFpEF, it would appear that this cohort is worthy
of targeted investigation. Nonpharmacological in-
terventions such as cardiac rehabilitation (15) may
address the emerging extracardiac targets in HFpEF.
Dietary interventions, such as the DASH-DHF (Effects
of the Dietary Approaches to Stop Hypertension
Sodium-Restricted Diet in Diastolic Heart Failure)
(16), are methods to address the metabolic abnor-
malities that lead to a salt-sensitive state and pheno-
typic expression of HFpEF. Novel pharmacological
therapies including endothelial nitric oxide synthase
activators, matrix metalloproteinase 9 inhibitors,
nitroxyl donors, and LCZ696, a combination drug of
angiotensin II receptor blocker and neprilysin inhibi-
tor, could be beneﬁcial. Each of these has attractive
properties, including antiﬁbrotic, antihypertrophic,
and antiadrenergic actions that oppose adverse car-
diac remodeling.
The main objective of phenotypic characterization
of the heterogeneous cohort that comprises HFpEF is
to identify a pathway forward for management of
older adult patients with HFpEF. Our hope is that such
lines of investigation provides more than proving the
obvious, namely, that diabetes and HFpEF are bad
diseases and worse in combination. However, only
after future carefully conducted investigations in
targeted populations will we know whether the
splitting into distinct phenotypes will be a fruitful
pathway forward.
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